Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Free Report) have been assigned a consensus rating of “Buy” from the ...

Viking Therapeutics (NASDAQ: VKTX) didn't exactly capture investors' hearts in the final month of 2024. The biotech company's ...

And one of them is Viking Therapeutics (NASDAQ: VKTX), which has a promising GLP-1 treatment in development that investors are hopeful will generate billions in revenue for the modestly sized ...

Viking Therapeutics, Inc. (VKTX ... Meanwhile, the Dow experienced a rise of 0.07%, and the technology-dominated Nasdaq saw a decrease of 0.05%. The the stock of company has fallen by 22.31% ...

In light of the above, Viking Therapeutics is not itself in trouble right now. The market's reaction to Merck's announcement assumes the very best outcome for its upcoming clinical trials for HS ...

Deep-pocketed investors have adopted a bullish approach towards Viking Therapeutics (NASDAQ:VKTX), and it's something market players shouldn't ignore. Our tracking of public options records at ...

Shares of Viking Therapeutics (VKTX) are down $2.70, or 6%, to $44.00 in pre-market trading following Merck (MRK) and Chinese biopharmaceutical company Hansoh Pharma’s announcement earlier that ...

Deep-pocketed investors have adopted a bearish approach towards Viking Therapeutics (NASDAQ:VKTX), and it's something market players shouldn't ignore. Our tracking of public options records at ...

Piper Sandler initiated coverage of Viking Therapeutics (VKTX) with an Overweight rating and $74 price target The company has generated one of the more compelling weight loss profiles in Phase 2 ...

The most recent trading session ended with Viking Therapeutics, Inc. (VKTX ... and the technology-centric Nasdaq increased by 1.03%. Coming into today, shares of the company had lost 19.64% ...

Our analysis of options history for Viking Therapeutics (NASDAQ:VKTX) revealed 9 unusual trades. Delving into the details, we found 66% of traders were bullish, while 22% showed bearish tendencies.